Legend Biotech Corp Stock Today
| LEGN Stock | USD 50.26 1.42 2.91% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Legend Biotech is selling at 50.26 as of the 11th of October 2024; that is 2.91% increase since the beginning of the trading day. The stock's open price was 48.84. Legend Biotech has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Legend Biotech Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of September 2024 and ending today, the 11th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of June 2020 | Category Healthcare | Classification Health Care |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. The company has 184.29 M outstanding shares of which 12.07 M shares are now shorted by private and institutional investors with about 12.36 trading days to cover. More on Legend Biotech Corp
Moving together with Legend Stock
Moving against Legend Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Legend Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLegend Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Legend Biotech's financial leverage. It provides some insight into what part of Legend Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Legend Biotech Corp (LEGN) is traded on NASDAQ Exchange in USA. It is located in 2101 Cottontail Lane, Somerset, NJ, United States, 08873 and employs 2,200 people. Legend Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.26 B. Legend Biotech Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 184.29 M outstanding shares of which 12.07 M shares are now shorted by private and institutional investors with about 12.36 trading days to cover.
Legend Biotech Corp currently holds about 791.26 M in cash with (384.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.11.
Check Legend Biotech Probability Of Bankruptcy
Ownership AllocationLegend Biotech Corp maintains a total of 184.29 Million outstanding shares. Over half of Legend Biotech's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Legend Ownership Details
Legend Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-06-30 | 1.7 M | |
| Federated Hermes Inc | 2024-06-30 | 1.5 M | |
| Citadel Advisors Llc | 2024-06-30 | 1.4 M | |
| Paradigm Biocapital Advisors Lp | 2024-06-30 | 1.2 M | |
| Timessquare Capital Management, Llc | 2024-06-30 | 1.2 M | |
| State Street Corp | 2024-06-30 | 1.1 M | |
| Alliancebernstein L.p. | 2024-06-30 | 1.1 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 1.1 M | |
| Matthews International Cap Mgmt Llc | 2024-06-30 | 1 M | |
| Fmr Inc | 2024-06-30 | 17.6 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 11.5 M |
Legend Biotech Historical Income Statement
Legend Stock Against Markets
Legend Biotech Corporate Management
| Elaine Qian | VP Resources | Profile | |
| James JD | General Counsel | Profile | |
| Lori CPA | Chief Officer | Profile | |
| Guowei Fang | Chief Development | Profile | |
| Tina Carter | Corporate Lead | Profile | |
| Steven Gavel | US Development | Profile | |
| Marc Harrison | VP Counsel | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 2.505 | Quarterly Revenue Growth 1.544 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.